Regeneron Pharmaceuticals is a biotechnology company founded in 1988 which originally focused on neurotrophic factors and their regenerative capabilities. Neurotrophic factors are a family of proteins that may be capable of regrowing damaged neurons.
The company has three products on the market: EYLEA, which treats elderly blindness, ARCALYST, which treats certain pediatric and neonatal inflammatory diseases, and ZALTRAP, for metastatic colorectal cancer.
Regeneron Pharmaceuticals trades publicly on the NASDAQ under the ticker symbol REGN, is #364 in the FT Gloabl 500, is #943 in the Fortune 1000, has 3,066 employees, and had $3.06 billion in revenue in 2014.
Regeneron PharmaceuticalsRegeneron Pharmaceuticals is a biotechnology company founded in 1988 which originally focused on neurotrophic factors and their regenerative capabilities. Neurotrophic factors are a family of proteins that may be capable of regrowing damaged neurons.
The company has three products on the market: EYLEA, which treats elderly blindness, ARCALYST, which treats certain pediatric and neonatal inflammatory diseases, and ZALTRAP, for metastatic colorectal cancer.
Regeneron Pharmaceuticals trades publicly on the NASDAQ under the ticker symbol REGN, is #364 in the FT Gloabl 500, is #943 in the Fortune 1000, has 3,066 employees, and had $3.06 billion in revenue in 2014.
I am an Eylea Patient, Part of the Eylea-4-U, program. A few years ago there was a claim form to copy for the future. That stopped.
Please resume ,or put mailing info on the website , so to not have to call in for info.